Dueling BRCA Databases: What About the Patient?
Posted April 20, 2017 by
The news release Monday morning grabbed my attention:
“Study finds wide gap in quality of BRCA1/2 variant classification between Myriad Genetics and a common public database.”
Myriad Genetics had been exclusively providing tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been offering tests for much lower prices. Meanwhile, Myriad has amassed a far deeper database than anyone else, having been in the business so much longer. And it’s proprietary.
.png)
No hay comentarios:
Publicar un comentario